GlycoNex Doses First Patient in Phase I Trial of Glycan-Directed ADC GNX1021 for Advanced Solid Tumors
核心洞察
GlycoNex has dosed the first patient in a first-in-human Phase I trial of GNX1021, a novel glycan-targeting antibody-drug conjugate, in Japan.
GNX1021 targets the branched Lewis B/Y glycan antigen (搜索) highly expressed in gastric and gastrointestinal cancers with limited normal tissue expression.
The multinational, multicenter trial will evaluate safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity across multiple dose levels.
GlycoNex Inc. (搜索) (TPEx: 4168) announced today that the first patient has been successfully dosed in the first-in-human (FIH) Phase I clinical trial of GNX1021, the company's novel glycan-targeting antibody-drug conjugate (ADC), in Japan. The milestone marks GNX1021's transition into clinical development and initiates the generation of the first human data for GlycoNex's lead oncology asset.
"The start of dosing represents an important value inflection point for GlycoNex," the company stated, noting that it advances GNX1021 from preclinical development into the clinic, reduces development uncertainty, increases the maturity of the asset, and establishes the foundation for clinical safety, pharmacokinetic, and early activity data that will define the program's future direction.
A Differentiated Glycan-Targeting Mechanism
GNX1021 is directed at the branched Lewis B/Y (bLeB/Y) glycan antigen, which is highly expressed in gastric cancer (搜索) and other gastrointestinal malignancies (搜索) while showing limited expression in normal tissue. Rather than targeting a single protein receptor — the approach taken by most ADCs currently in development — GNX1021 recognizes a tumor-associated glycan structure presented across multiple carrier molecules on the cancer-cell surface.
This differentiated mechanism is designed to broaden the pool of addressable targets, enhance tumor selectivity, and address the therapeutic challenges posed by tumor heterogeneity, positioning GNX1021 distinctly within a competitive ADC landscape. GNX1021 is the lead program to emerge from GlycoNex's proprietary GlycoSH anti-glycan antibody library, which continues to generate a pipeline of glycan-directed ADCs and related candidates.
"Dosing the first patient in the GNX1021 Phase I trial is a major achievement for GlycoNex and an important value inflection point for our oncology portfolio," said Dr. Mei-Chun Yang, President and CEO of GlycoNex. "GNX1021 is designed to address tumor-associated glycan structures that conventional protein-targeted therapies may not adequately capture. Advancing this differentiated program into the clinic allows us to evaluate its potential in patients while building a stronger foundation for future development and strategic collaboration."
Phase I Trial Design and Objectives
The FIH study is a multinational, multicenter Phase I trial being conducted in Japan and Taiwan in patients with advanced solid tumors (搜索). The trial will evaluate GNX1021 across multiple dose levels for safety and tolerability, pharmacokinetics, immunogenicity, preliminary anti-tumor activity, and the recommended dose for subsequent development.
Data from the study are expected to inform dose selection and the future development strategy for GNX1021, including its potential evaluation in selected gastrointestinal cancer populations.
Strategic Collaboration Opportunities
GlycoNex intends to explore potential regional and global licensing, co-development, and other strategic collaboration opportunities for GNX1021. The company will continue to advance the program within its broader glycan-directed oncology pipeline and assess the development and partnership strategies most appropriate for its long-term clinical and commercial development.
GlycoNex Inc. (搜索) is a clinical-stage biotechnology company headquartered in New Taipei City, Taiwan, focused on glycan-directed ADCs and biosimilars. In addition to GNX1021, the company is also developing SPD8, a denosumab biosimilar in collaboration with Mitsubishi Gas Chemical, which has completed a Phase III clinical study and is preparing for marketing authorization application.